Research Findings on Tesamorelin and Adipose Tissue Quality in HIV

In a Phase 3 clinical analysis conducted by Lake et al. (2021), researchers investigated how the synthetic peptide tesamorelin, a growth hormone-releasing hormone (GHRH) analogue, influences adipose tissue quality in adults living with HIV who have central adiposity. Tesamorelin has been approved for treating HIV-associated lipodystrophy, a condition characterized by abnormal fat accumulation, particularly in the abdomen. While previous trials had demonstrated that tesamorelin significantly reduces visceral adipose tissue (VAT) quantity in people living with HIV, the Lake et al. study specifically examined whether the peptide also affects fat density, which is a marker of adipose tissue quality independent of total fat volume.
According to the methodology described by Lake and colleagues, the analysis used data pooled from two completed, randomized, placebo-controlled trials in which participants were adults (18–65 years old) living with HIV on stable antiretroviral therapy and had evidence of central adiposity. Participants were randomized to receive a daily subcutaneous injection of 2 mg tesamorelin or placebo for 26 weeks. The researchers defined a therapeutic response as at least an 8% decrease in VAT area on CT imaging, with approximately 70% of tesamorelin-treated subjects meeting this criterion. For the purpose of this analysis, only participants who responded to tesamorelin and those in the placebo arm were included. CT scans were analyzed by a blinded reader to measure both VAT and subcutaneous adipose tissue (SAT) density in Hounsfield units (HU), where higher HU values reflect denser, smaller adipocytes, a characteristic of higher-quality adipose tissue.

The results reported by Lake et al. (2021) showed that after 26 weeks, participants treated with tesamorelin experienced statistically significant increases in both VAT and SAT density compared with placebo. Mean VAT density increased by 6.2 HU in the tesamorelin group versus 0.3 HU in the placebo group (p < 0.0001), and SAT density increased by 4.0 HU versus 0.3 HU for placebo (p < 0.0001). These density changes persisted even after controlling for baseline density and fat area, indicating that tesamorelin’s effects on adipose tissue quality were independent of changes in total fat quantity. The study also explored relationships between adipose tissue density and metabolic biomarkers, finding baseline correlations with measures such as insulin resistance and cholesterol, though these relationships varied across markers and required further investigation.
The analysis by Lake and colleagues expands the scientific understanding of tesamorelin’s biological activity by showing that, in addition to reducing visceral fat volume, tesamorelin may improve the quality of adipose tissue in adults with HIV-associated central adiposity. These findings suggest that the peptide’s impact on fat quality could have implications for metabolic health independent of fat loss, though further research is necessary to clarify the physiological significance of these density changes and their relationships with cardiometabolic outcomes.

Important Notice
This content is provided for educational and informational purposes only. The research discussed relates exclusively to laboratory and clinical investigation. No claims are made regarding biological activity, therapeutic use, or outcomes beyond what was observed in the study. Peptides referenced are not intended for human or veterinary use outside of controlled research contexts.

Sources
Lake J. E. et al. (2021). Tesamorelin improves fat quality independent of changes in fat quantity. AIDS.